Long-Term STDs and Cancer: Which Infections Raise Your Risk

Published: March 2025 | Last updated: May 2026

The link between sexually transmitted infections and certain cancers is well documented in oncology research, though the picture is more specific than the headlines suggest. Most STIs do not cause cancer at all. A small number can, and almost always only after years of untreated persistent infection. Roughly 10% of cancers diagnosed worldwide in 2022 were attributed to cancer-causing infections (WHO, cancer fact sheet), with HPV, hepatitis B and C, and HIV doing most of the work in sexual-health contexts. The good news: vaccination, routine screening, and timely treatment break that chain in the vast majority of cases.

This article walks through the infections that carry real cancer risk, the cancers they're linked to, and the testing and prevention steps that move the needle. Where research is mixed or weak, you'll see that called out plainly rather than dressed up.

This article is published by stdrapidtestkits.com, which sells at-home STI testing kits. We recommend products based on fit-for-purpose for the reader's concern, not commercial benefit.

How a chronic infection turns into cancer

Cancer almost never starts with a single insult. It builds up over years through repeated cycles of cell damage, inflammation, and DNA error. Persistent infections can drive every step of that process.

Three broad mechanisms account for most infection-driven cancers:

• Direct cellular hijack. Some viruses make proteins that disable the cell's normal brakes on division. High-risk HPV strains produce two such proteins (E6 and E7) that interfere with the tumor-suppressor proteins p53 and Rb. When those brakes fail and the infection persists for years, the cell can accumulate the mutations needed to become cancerous. Hepatitis B virus can also insert its own genetic material into liver-cell DNA, contributing to the same pathway.
• Immune surveillance failure. A healthy immune system finds and destroys precancerous cells before they grow. HIV undermines that surveillance by depleting CD4 T-cells, which is why people with untreated HIV develop cancers driven by other oncogenic viruses (HPV, Epstein-Barr virus, Kaposi sarcoma-associated herpesvirus) at much higher rates than the general population.
• Chronic inflammation and tissue damage. Long-running infections (hepatitis B and C in the liver; chlamydia, trichomoniasis, untreated syphilis in genitourinary tissues) keep immune cells active in one location for years. That sustained inflammation produces reactive molecules and growth signals that damage DNA and select for abnormal cells.

Each pathway takes time. The cervical-cancer arc from initial HPV infection to invasive cancer typically runs 15 to 20 years in healthy women, and longer with vaccination or screening. Liver cancer from chronic hepatitis usually takes decades. That long lag is why screening works so well: between infection and cancer there's almost always a wide treatable window.

It's also why a positive STI test is rarely a cancer scare in itself. What you're managing clinically is the chance of an infection persisting untreated for years, which is what allows the slow path toward cellular damage to play out.

HPV: the leading viral cause of STI-related cancer

Human papillomavirus is the most studied and most consequential link between STIs and cancer. The CDC states that long-lasting infection with certain HPV types can cause cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers (CDC, about HPV and cancer). There are more than 200 known HPV types; about 14 are classified as high-risk for cancer, with types 16 and 18 driving most of the disease burden. HPV is responsible for a large share of the cancers diagnosed in the United States each year.

HPV is also extremely common. The CDC describes it as so widespread that nearly all sexually active people get it at some point in their lives. Most infections clear on their own within one to two years and never cause symptoms. A persistent infection with a high-risk type is what drives cancer risk, and crucially the cancer-driving strains are not the ones that cause visible genital warts. Someone can carry HPV 16 for years without any outward sign, which is why visible symptoms are not a reliable filter for cancer-relevant infection.

HPV strain groups at a glance

Cancers linked to HPV, and what protects against them

Persistent high-risk HPV is tied to cancers at several body sites. The share of cases it drives is documented by the U.S. National Cancer Institute:

• Cervical cancer. Virtually all cervical cancers are caused by HPV.
• Anal cancer. More than 90% of anal cancers are HPV-linked.
• Oropharyngeal cancer. About 70% of cancers of the back of the throat, base of the tongue, and tonsils are HPV-linked, and the share has been rising in men over the past two decades.
• Penile cancer. Roughly 63% of cases are HPV-linked, though penile cancer overall is uncommon.
• Vaginal and vulvar cancers. About 75% of vaginal and 69% of vulvar cancers are HPV-linked.

The American Cancer Society lists the same broad set of HPV-driven cancers across both sexes (ACS, HPV and cancer), which is why HPV is no longer treated as a women's-health-only concern.

What protects against HPV-related cancer

The HPV vaccine (Gardasil 9 in the U.S.) covers nine high-risk and wart-causing strains, including types 16 and 18. ACIP recommends routine vaccination at ages 11 to 12 with catch-up through age 26. Adults aged 27 to 45 may benefit from vaccination after shared clinical decision-making with a clinician, depending on personal risk. Even after sexual debut the vaccine can still protect against strains the person has not yet encountered.

For people with a cervix, the screening pathway is well established: a Pap test or an HPV test (or both) on the schedule your clinician recommends, typically every 3 to 5 years for average-risk adults. Pre-cancerous changes are highly treatable.

For other anatomic sites (anus, throat, penis), there is no broadly recommended general-population screening. Men in particular face a screening gap that the HPV vaccine partly compensates for. Risk reduction relies on vaccination, condom use (which lowers but does not eliminate transmission), and prompt evaluation of any persistent oropharyngeal, anal, or genital lesion.

HPV Rapid Self-Test (Women Only)

Papillomavirus (HPV) At-Home Rapid Self-Test Kit

$59.00

Self-collected vaginal swab that screens for HPV at home in about 15 minutes. Validated for female anatomy only; we don't sell a male HPV test, and Pap-based screening at a clinic remains the recommended cervical-cancer prevention pathway. The at-home swab works as a privacy-friendly screening complement to routine Pap surveillance, not a replacement for it.

Test for HPV

HIV: immune suppression amplifies cancer risk

HIV does not directly cause most of the cancers seen in people living with the virus. The mechanism is indirect, though powerful: untreated HIV gradually depletes CD4 T-cells, the immune cells that normally identify and destroy abnormal or virus-infected cells before they grow into tumors. With that surveillance weakened, other oncogenic infections (HPV, Epstein-Barr virus, Kaposi sarcoma-associated herpesvirus) get more room to cause disease.

Cancers more common in people with HIV

• Kaposi sarcoma. Caused by Kaposi sarcoma-associated herpesvirus (KSHV / HHV-8), this cancer is far more common in people with untreated HIV. The U.S. National Cancer Institute reports that people with HIV are more than 200 times as likely to develop Kaposi sarcoma as the general population. It can appear in the skin, mouth, lymph nodes, lungs, and gut.
• Non-Hodgkin lymphoma. Several lymphoma subtypes, many of them Epstein-Barr-virus-related, occur at substantially higher rates in people with HIV.
• Cervical cancer. Women living with HIV have higher rates of persistent HPV infection and faster progression from precancerous changes to invasive cancer.
• Anal cancer. Anal HPV infection is more common and more persistent in people with HIV, particularly men who have sex with men.
• Liver and lung cancers. Smaller but still meaningful elevated risks remain even in the antiretroviral-therapy era, partly because of overlapping hepatitis or smoking exposures.

What lowers the risk

Effective antiretroviral therapy (ART), started promptly after diagnosis and continued lifelong, restores most of the immune surveillance that HIV strips away. People who maintain an undetectable viral load on ART have cancer rates much closer to (though still slightly higher than) the HIV-negative population, especially for AIDS-defining cancers. The CDC and major HIV-care guidelines treat early diagnosis followed by immediate ART as the single most impactful step against HIV-associated cancer risk. For HIV-negative people at higher exposure risk, pre-exposure prophylaxis (PrEP) substantially reduces transmission and removes the entry point to that elevated-risk pathway entirely.

Routine HIV testing is the connector. The U.S. Preventive Services Task Force recommends one-time HIV screening for all adults aged 15 to 65, with more frequent testing for people at higher risk. You can also reach for an at-home HIV test that returns a result in around 15 minutes; any positive rapid result should be confirmed with a laboratory test before any clinical action.

Hepatitis B and C: the liver-cancer connection

Both hepatitis B and hepatitis C can be spread through sexual contact, although for hepatitis C the dominant routes worldwide remain blood-to-blood (shared needles, tattoo equipment in unregulated settings, historical healthcare exposures). Sexual transmission of HCV is well documented but accounts for a smaller share of total infections; HBV by contrast is highly infectious through both blood and bodily fluids and transmits sexually quite efficiently.

Both viruses can cause chronic infection of liver cells. Over years to decades, that chronic infection can progress through fibrosis to cirrhosis and, in a subset of people, to hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The World Health Organization's hepatitis B fact sheet links chronic HBV infection to cirrhosis and liver cancer, and the WHO hepatitis C fact sheet describes the same fibrosis-cirrhosis pathway for HCV. Together the two viruses account for the majority of primary liver cancer worldwide.

Risk reduction is well defined

• Hepatitis B vaccine. Routine for U.S. infants since the early 1990s and recommended by CDC for all unvaccinated adults aged 19 to 59. Three doses produce long-lasting protection. The vaccine prevents both acute infection and the long-term cancer risk that follows chronic infection.
• Hepatitis C cure. Direct-acting antiviral treatment cures more than 95% of hepatitis C cases in 8 to 12 weeks. Curing the infection before significant liver scarring occurs largely eliminates the cancer-risk pathway.
• Screening. CDC recommends one-time hepatitis C testing for all adults aged 18 and older, plus testing during every pregnancy and ongoing testing for people with continued risk. Hepatitis B testing is recommended at least once for all adults aged 18 and older.

Both viruses can sit silently in the body for years before any symptoms appear. By the time someone develops jaundice, abdominal swelling, or unexplained fatigue, liver damage is often already extensive. Testing is the only reliable way to find these infections early, and the testing pathway has become dramatically simpler over the last decade.

Chlamydia, gonorrhea, and trichomoniasis: chronic-inflammation links

The three most common bacterial and parasitic STIs in this category share a pattern: they often cause no symptoms, they can persist for months or years if untreated, and the cancer-risk research focuses on the consequences of that chronic, low-grade inflammation rather than on direct viral oncogenesis.

What the evidence shows

• Chlamydia. Untreated chlamydia is the leading preventable cause of pelvic inflammatory disease (PID) and tubal-factor infertility in women. Several epidemiologic studies have reported associations between chronic chlamydia infection and a modestly elevated risk of cervical cancer, possibly mediated by chronic cervical inflammation that worsens HPV persistence. A few studies have also examined possible associations with ovarian cancer, with inconsistent results. Direct causation has not been established; the strongest argument for prompt treatment remains PID and infertility prevention, with any cancer-risk reduction as a secondary benefit. You can screen privately with an at-home chlamydia and gonorrhea test.
• Gonorrhea. Like chlamydia, gonorrhea can cause PID in women and chronic urethritis or epididymitis in men. Some studies have reported associations with prostate cancer in men with a history of repeated or chronic gonorrhea infection, again most likely through inflammation rather than direct causation. Antibiotic resistance is a separate and growing concern; CDC regularly updates first-line treatment recommendations.
• Trichomoniasis. A protozoan parasite, Trichomonas vaginalis is the most common curable non-viral STI worldwide. Research has found associations between Trichomonas infection and prostate cancer in men, and between Trichomonas and cervical pre-cancer in women, though as with the others, causality is inferred rather than proven. Trichomoniasis is fully curable with a short course of antibiotics.

The pattern across all three: untreated chronic infection appears to act as a risk amplifier when it co-exists with high-risk HPV, with general inflammation in the prostate, or in the immune-compromised. Treatment is straightforward and effective in nearly all cases. The challenge is detection, because symptoms are often absent.

Note on our trichomoniasis kit's gender scope

Our at-home trichomoniasis rapid swab is validated for vaginal self-collection only. Male readers needing trichomoniasis testing should see a clinic, where urethral swab and urine-based testing are available.

Herpes and syphilis: weaker but real signals

The cancer-risk evidence for herpes simplex virus and syphilis is less clear-cut than for HPV, HIV, or hepatitis. Both can produce chronic or recurrent inflammation in tissues that matter for cancer biology, though the population-level signal is more modest and more contested.

• HSV-2. Some older studies suggested a link between herpes simplex virus type 2 and cervical cancer. With more rigorous methods, that signal has weakened, and most modern reviews treat HPV as the dominant driver of cervical cancer with HSV-2 as, at most, a co-factor. A handful of studies have looked at HSV-2 and prostate cancer with similarly modest results.
• Syphilis. Untreated syphilis can persist for decades and cause systemic inflammation. The cancer-risk literature on syphilis is older and smaller, though some studies have reported associations with elevated rates of certain cancers, plausibly via long-term inflammation and immune disruption. Syphilis is fully curable with penicillin.

For both, the practical takeaway is the same as for the other infections in this article: detect early, treat or manage promptly, and the cancer-risk pathway largely closes.

What at-home tests can (and cannot) tell you

One point that gets lost between clinic visits and search results: even a comprehensive STI panel does not screen for cancer or for precancerous cell changes (a category called dysplasia, where cells look abnormal under a microscope but have not yet become invasive cancer). A negative HPV swab does not rule out dysplasia. A positive HIV antibody result tells you nothing about whether cancer has developed. The two are different tests answering different questions.

At-home rapid lateral-flow tests are screening tools. They use the same antibody or antigen targets that a clinic uses, in a faster and simpler format that trades some analytical sensitivity (especially compared with laboratory NAAT or PCR) for speed, privacy, and convenience. Used after the correct window period, they reliably answer the question "do I currently carry an infection that needs follow-up?"

What they do not do is replace a Pap test, a liver ultrasound, an anal-Pap follow-up, or any other cancer-specific screening. A positive screening result is a signal to confirm with a lab and start treatment. A negative result is a baseline, not a guarantee of cancer-free status, especially for HPV where the cancer-screening pathway is the Pap test rather than the antibody test.

Practical prevention: what works

The headline-friendly fact about STI-related cancer is that almost all of it is preventable. Three categories of intervention do most of the work.

Vaccination

HPV and hepatitis B both have effective vaccines that prevent the chronic-infection pathway entirely. Both are recommended for adolescents in the U.S. with catch-up windows that extend into adulthood. The HPV vaccine has produced measurable population-level drops in HPV 16 and 18 prevalence and in cervical pre-cancer rates among vaccinated cohorts. The hepatitis B vaccine has been routine in the U.S. childhood schedule since the early 1990s, with global coverage cutting new chronic infections in children dramatically since then.

Screening

Cervical screening (Pap test, HPV test, or co-testing) catches almost all pre-cancerous cervical changes well before they become invasive cancer. Hepatitis B and C screening, now recommended one-time for all U.S. adults, identifies chronic infections early enough to treat or cure. HIV testing, recommended at least once for all U.S. adults aged 15 to 65, opens the door to ART before significant immune damage occurs. For people living with HIV, anal Pap screening is increasingly recommended, particularly for men who have sex with men.

Treatment

Bacterial and parasitic STIs (chlamydia, gonorrhea, trichomoniasis, syphilis) are curable with appropriate antibiotics. Hepatitis C is curable in over 95% of cases with 8 to 12 weeks of direct-acting antivirals. HIV cannot be cured, though daily ART produces an undetectable viral load and keeps the disease fully manageable for life. Each of these treatments closes (or substantially narrows) the path from infection to cancer.

Barrier methods and routine testing as the connector

Condoms reduce transmission of bloodborne and many fluid-borne STIs significantly. They are less effective against skin-to-skin viruses like HPV and herpes, where exposed skin outside the condom can still transmit. Vaccination and treatment only help if infections get detected, and in U.S. STI care the bottleneck is screening uptake, not access to treatment. At-home rapid tests, mailed PCR panels, and free clinic services all work toward the same goal of making testing cheaper, faster, and more private so more people follow through.

When to test, and what to test for

The right testing schedule depends on your age, sexual activity, and risk profile. A few baseline recommendations apply broadly:

• HIV: at least once for all adults aged 15 to 65; annually or more often for sexually active gay and bisexual men, anyone with multiple partners, and people who inject drugs.
• Chlamydia and gonorrhea: annually for all sexually active women under 25, sexually active gay and bisexual men, and pregnant women. Older adults with new or multiple partners benefit from annual testing as well.
• Syphilis: annually for sexually active gay and bisexual men, pregnant women (at first prenatal visit), and people with HIV.
• Hepatitis B and C: at least once for all adults aged 18 and older, with repeat testing for ongoing risk.
• HPV / cervical screening: Pap test starting at age 21, then HPV-based testing or co-testing on the schedule your clinician recommends.

Beyond the schedule, test after any specific exposure event you're worried about. Window periods vary by infection: HIV antibody tests are reliable from about 23 to 90 days post-exposure depending on the assay (lab-based 4th-generation antigen/antibody combo tests can detect from around 23 days; home rapid antibody-only tests are more reliably interpreted from 45 to 90 days post-exposure). Chlamydia and gonorrhea swabs are reliable from about 1 to 2 weeks; syphilis blood tests are typically reliable from 3 to 6 weeks. A negative test inside the window doesn't fully rule out infection; a follow-up test at the end of the window is worth doing if there's a real concern.

8-in-1 Comprehensive STI Home Test Kit

Complete 8-in-1 STD At-Home Rapid Test Kit

$472.00

Our most comprehensive at-home multi-test kit, covering eight common sexually transmitted infections (including HIV, hepatitis B, hepatitis C, syphilis, chlamydia, gonorrhea, and herpes) in a single panel. A practical broad screen when you want to cover most of the cancer-relevant viral STIs in one kit. Fingerstick blood plus self-collected swab samples; full panel results in about 15 to 20 minutes. Validated for both men and women.

See the 8-in-1 Kit

1. U.S. Centers for Disease Control and Prevention. HPV (Human Papillomavirus) basics, transmission, and the HPV-associated cancer link.
2. World Health Organization. Hepatitis B fact sheet, including the link from chronic HBV infection to cirrhosis and hepatocellular carcinoma.
3. World Health Organization. Hepatitis C fact sheet, including the fibrosis-cirrhosis-liver-cancer pathway and the more-than-95% direct-acting antiviral cure rate in 8 to 12 weeks.
4. U.S. National Cancer Institute. HPV and Cancer: share of cervical, anal, oropharyngeal, penile, vaginal, and vulvar cancers attributable to HPV.
5. U.S. National Cancer Institute. HIV Infection and Cancer Risk fact sheet, covering AIDS-defining and non-AIDS-defining cancers and the more-than-200-times elevated Kaposi sarcoma risk in people with HIV.
6. American Cancer Society. HPV and Cancer: the cancers HPV is known to cause in adults across both sexes.

Sam Harper

Sam covers at-home sexual-health testing, public-health guidance, and clinical-testing basics for general audiences. Has been writing about consumer health since 2019, with a focus on translating CDC and WHO guidance into plain-English action items. Not a clinician; articles are summaries, not advice.